Results 211 to 220 of about 532,969 (259)
Some of the next articles are maybe not open access.
Production systems for recombinant antibodies
Frontiers in Bioscience, 2008Recombinant antibodies are the fastest growing class of therapeutic proteins. Furthermore, antibodies are key detection reagents in research and diagnostics. The increasing demand for antibodies with regards to amount and quality resulted in the development of a variety of recombinant production systems employing gram-negative and gram-positive ...
Thomas, Schirrmann +3 more
openaire +2 more sources
Recombinant Antibodies in Cancer Therapy
Current Protein & Peptide Science, 2006The application of recombinant immunotoxin and radioimmunoconjugate in Cancer therapy has revived the "magic bullet" concept predicted a century ago. Many of the recombinant antibodies have received FDA approval for various indication of cancer in recent years and numerous others are in clinical trials.
M S, Nayeem, Rizwan H, Khan
openaire +2 more sources
Engineering recombinant antibodies for immunotherapy
Cell Biophysics, 1995Recombinant antibody fragments binding with high affinity to their target can be obtained either from hybridomas or directly from antibody libraries on filamentous phage. These fragments are devoid of any activity other than antigen binding, and have to be processed and functionalized in order to be suitable for clinical applications.
D, Neri, H, Petrul, G, Roncucci
openaire +2 more sources
The use of recombinant antibodies in proteomics
Current Opinion in Biotechnology, 2000Recombinant antibodies are becoming increasingly important in the field of proteomics. Recent advances include the development of large phage-antibody libraries that contain high-affinity binders to almost any target protein, and new methods for high-throughput selection of antibody-antigen interactions.
L J, Holt +3 more
openaire +2 more sources
Recombinant antibody fragment production
Methods, 2017Recombinant antibodies are now very important in both therapeutics and diagnostics and offer significant advantages over conventional antibodies. The generation of a single-chain variable antibody fragment (scFv) (a common and important recombinant antibody format) is used to demonstrate the construction of a recombinant antibody library. An immunotube-
H, Ma, R, O'Kennedy
openaire +2 more sources
Recombinant monoclonal antibody technology
Transfusion Clinique et Biologique, 2002With the development of murine hybridoma technology over a quarter century ago, the ability to produce large quantities of well-characterized monoclonal antibody preparations revolutionized diagnostic and therapeutic medicine. For many applications in transfusion medicine, however, the production of serological reagents in mice has certain biological ...
openaire +2 more sources
Recombinant antibodies for cancer therapy
Expert Opinion on Biological Therapy, 2008Recombinant antibodies have evolved into successful therapeutics with 10 approved for cancer and more in the pipeline. Four of the top ten cancer therapy drugs are recombinant antibodies.To survey the current state-of-the-art highlighting the reasons for this success and looking ahead to the next generation of antibody therapy.An analysis was carried ...
openaire +2 more sources
The Structure of Natural and Recombinant Antibodies
2015Immunoglobulins (Ig) isotypes A, D, E, G, and M are glycoproteins which are mainly composed of a "Y"-shaped Ig monomer (~150 kDa), consisting of two light and two heavy chains. Both light and heavy chains contain variable (N-terminal) and constant regions (C-terminal).
Hui, Ma, Richard, O'Kennedy
openaire +2 more sources
Glycosylation of Recombinant Antibody Therapeutics
Biotechnology Progress, 2008The adaptive immune system has the capacity to produce antibodies with a virtually infinite repertoire of specificities. Recombinant antibodies specific for human targets are established in the clinic as therapeutics and represent a major new class of drug.
openaire +2 more sources
Recombinant antibodies: back to the future
Australian and New Zealand Journal of Medicine, 1993Ward, R. L., Hawkins, N. J.
openaire +5 more sources